Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm)
NCT ID: NCT02088762
Last Updated: 2016-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
325 participants
OBSERVATIONAL
1997-01-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background: Early recognition and appropriate excision play a crucial role in management of malignant melanoma, while the size of surrounding normal skin that should be excised is area of controversies.
Methods: The investigators will conduct a retrospective population-based survey in patients with primary melanoma 2 mm≤ in thickness undergoing tumor excision with 1 cm and 2 cm margins in the investigators center. For both groups, the patients' charts reviewed for data including patient gender, age, tumor location, tumor type, Clark's level, Breslow thickness, tumor type, presence of ulceration, findings of sentinel nodes, local recurrences, locoregional metastases, disease free survival and overall survival were calculated for both groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of Surgical Excision Margins in Thick Primary Melanoma
NCT01183936
Trial of Surgical Excision Margins in Thick Primary Melanoma - 2
NCT03638492
Review of the Literature and Serie of Patients Who Underwent Reconstruction After Wide Local Excision of Nail Apparatus for Melanoma
NCT06861023
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
NCT01720407
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Early recognition and appropriate excision play a crucial role in management of malignant melanoma, while the size of surrounding normal skin that should be excised is area of controversies.
Objective
To investigated the impact of the excision of melanoma 2mm≤ in thickness with 1cm surgical margins on survival of the patients compared with 2 cm surgical margins.
Methods
The investigators will conduct a retrospective population-based survey in patients with primary melanoma 2 mm≤ in thickness undergoing tumor excision with 1 cm and 2 cm margins in the investigators center. For both groups, the patients' charts reviewed for data including patient gender, age, tumor location, tumor type, Clark's level, Breslow thickness, tumor type, presence of ulceration, findings of sentinel nodes, local recurrences, locoregional metastases, disease free survival and overall survival were calculated for both groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 cm safety margin
1 cm safety margin
surgical excision
comparison of safety margin 1 versus 2 cm
2 cm safety margin
2 cm safety margin
surgical excision
comparison of safety margin 1 versus 2 cm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
surgical excision
comparison of safety margin 1 versus 2 cm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Safety margin 1 cm or 2 cm
* Tumor thickness according to Breslow \>2mm
Exclusion Criteria
* Unclear safety margins
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert E Hunger, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology, University of Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Dermatology
Bern, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-08-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.